Clinical Trials Underway
Synlogic is currently conducting clinical trials to evaluate the safety and tolerability of our Synthetic Biotic™ medicines to treat phenylketonuria (SYNB1618), and advanced solid tumors and lymphoma (SYNB1891), conditions with unmet medical needs. We are also working to advance new medicines for metabolic diseases and autoimmune and inflammatory diseases.
SYNB1618 is an orally delivered investigational living medicine that is designed to break down phenylalanine, an amino acid component of dietary protein. People with PKU do not break down phenylalanine efficiently which can lead to neurological disorders and decline. Synlogic has demonstrated that a liquid formulation of SYNB1618 can break down phenylalanine in the gut of both healthy volunteers and patients. Synlogic is conducting a bridging study in healthy volunteers of a solid oral formulation of SYNB1618 to determine its safety and tolerability and to select a suitable dose for testing in subsequent clinical trials in patients with PKU.
Oncology: Solid Tumors and Lymphoma
Immunotherapies have become the standard of care for many cancers, but more than half of patients fail to respond to treatment. SYNB1891 is an intratumorally delivered investigational living medicine that is designed to activate the immune system. Synlogic has initiated a Phase 1 clinical study of intratumorally administered SYNB1891 in patients with advanced solid tumors and lymphoma. More information can be found at www.clinicaltrials.gov